Zaltidine

Cat. No.: HY-15541
CAS No.: 85604-00-8
Molecular Formula: C₈H₁₀N₆S
Molecular Weight: 222.27
Target: Histamine Receptor
Pathway: GPCR/G Protein; Immunology/Inflammation
Storage: Powder -20°C 3 years
        4°C 2 years
        In solvent -80°C 6 months
        -20°C 1 month

SOLVENT & SOLUBILITY

In Vitro    H₂O : 7.69 mg/mL (34.60 mM; Need ultrasonic)

Preparing Stock Solutions

<table>
<thead>
<tr>
<th>Solvent Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>4.4990 mL</td>
<td>22.4952 mL</td>
<td>44.9903 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.8998 mL</td>
<td>4.4990 mL</td>
<td>8.9981 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.4499 mL</td>
<td>2.2495 mL</td>
<td>4.4990 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description
Zaltidine (CP-57361) is a H₂-receptor antagonist, which has the antisecretory action. IC₅₀ Value: Target: H₂ receptor in vitro: in vivo: In eight healthy male volunteers single oral doses of 5 mg, 25 mg and 100 mg produced dose-related inhibition of basal and pentagastrin-stimulated acid output (M.A.O.) with an estimated ID₅₀ of 40 mg for the latter. In eight subjects with duodenal ulceration single 100 mg and 200 mg doses produced 85% and 97% inhibition of M.A.O. at peak (3 h post-dose) and 20% and 23% inhibition at 24 h, respectively; inhibition of basal acid output was 97% at 3 h and 50% at 24 h with both doses [1]. One hundred and thirty-five patients were randomly allocated to 4 weeks’ treatment with either 150 mg zaltidine once daily or placebo. Fifty-nine were treated for a full 4 weeks with zaltidine before the trial was stopped. Healing rates after 4 weeks of zaltidine and placebo were 86% and 19%, respectively (p less than 0.001) [2].

REFERENCES